[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-245528-105":53,"doc-detail-245528-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","q3-2025-results-conference-call-and-webcast-for-investors-and-analysts","Q3 2025 Results - Conference call and webcast for investors and analysts","","Q3 2025 Results presentation for investors and analysts, highlighting strong group performance and upgraded FY2025 guidance. Covers key financial growth drivers including sustained Specialty Medicines sales, Core EPS and Core operating profit improvements, and cash generation supporting investment and shareholder returns. Includes a section on adjusted (non-IFRS) measures and detailed guidance and outlooks, plus a comprehensive cautionary statement on forward-looking statements, assumptions, risks, and disclosure references.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/q3-2025-results-conference-call-and-webcast-for-investors-and-analysts/245528/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/q3-2025-results-conference-call-and-webcast-for-investors-and-analysts/245528.png","ImageObject",442,249,{"name":88,"@type":89},"Ezra","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-22","2026-09-12",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",10,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What are the main highlights of Q3 2025 performance?","Question",{"text":109,"@type":110},"The presentation emphasizes strong group performance, upgraded FY2025 guidance, and sustained growth in Specialty Medicines, alongside improvements in Core EPS and Core operating profit supported by cash generation.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What is covered in the forward-looking statements cautionary section?",{"text":114,"@type":110},"It explains what constitutes forward-looking statements, provides examples of related wording, notes the Group’s lack of obligation to update them, and highlights that results can differ due to assumptions, risks, and uncertainties.",{"name":116,"@type":107,"acceptedAnswer":117},"How does the presentation handle guidance and outlooks?",{"text":118,"@type":110},"It instructs readers to review guidance and outlooks together with specific disclosure sections in related materials, and states that outlook statements are given on a CER basis using defined exchange-rate assumptions.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},245528,1791718489,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":37,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":20},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","29 October 2025  \nQ3 2025 Results  \nConference call and webcast for investors and analysts  \n [gsk.com](gsk.com)  \nQ3 2025 strong performance improves further  \nEmma Walmsley  \nPerformance: growth drivers  \nLuke Miels and Deborah Waterhouse  \nQ3 2025 financial performance  \nJulie Brown  \nSummary and Q&A  \nEmma Walmsley, Luke Miels, Deborah Waterhouse, Julie Brown, Tony Wood and David Redfern  \n2  \n Cautionary statement regarding forward-looking statements  \nThis presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.  \nOther than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC) . All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.  \nForward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under ‘Risk factors’ in the Group’s Annual Report on Form 20-F for the full year (FY) 2024. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directorson the date of this presentation.  \nA number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Group’s Q3 2025 Results and the Group’s Annual Report on Form 20-F for FY 2024.  \nAll expectations, guidance and outlooks regarding future performance and the dividend should be read together with the section “Guidance and outlooks, assumptions and cautionary statements on pages 52-53 of our stock exchange announcement of the Group’s Q3 2025 Results, the section “Assumptions and basis of preparation related to 2025 guidance, 2021-26 and 2031 outlooks” in the Appendix of this presentation and the statements on page 341 of the Group’s Annual Report for FY 2024.  \n3  \nQ3 2025 strong performance improves further  \nEmma Walmsley, Chief Executive Officer  \n2025 strong performance improves further  \nFY2025 Guidance upgraded  \nQ3 performance again demonstrates quality and strength of GSK portfolio  \nSales driven by sustained growth in Specialty Medicines (+16%): RI&I, Oncology and HIV  \nOur 4th FDA approval and excellent R&D progress supports l","cbCaioZJdoiIslvk","https://ap.wps.com/l/cbCaioZJdoiIslvk","pdf",683068,"English","# Q3 2025 Results\n## Conference call and webcast for investors and analysts\n## Q3 2025 strong performance improves further\n## Cautionary statement regarding forward-looking statements\n## Performance: growth drivers\n## Q3 2025 financial performance\n## Summary and Q&A","[{\"question\":\"What are the main highlights of Q3 2025 performance?\",\"answer\":\"The presentation emphasizes strong group performance, upgraded FY2025 guidance, and sustained growth in Specialty Medicines, alongside improvements in Core EPS and Core operating profit supported by cash generation.\"},{\"question\":\"What is covered in the forward-looking statements cautionary section?\",\"answer\":\"It explains what constitutes forward-looking statements, provides examples of related wording, notes the Group’s lack of obligation to update them, and highlights that results can differ due to assumptions, risks, and uncertainties.\"},{\"question\":\"How does the presentation handle guidance and outlooks?\",\"answer\":\"It instructs readers to review guidance and outlooks together with specific disclosure sections in related materials, and states that outlook statements are given on a CER basis using defined exchange-rate assumptions.\"}]","Q3 2025 Results - Conference call and webcast for investors and analysts | PDF",1789229277]